Total Payments
$15,604
2024 Payments
$98.25
Companies
9
Transactions
28
Medicare Patients
101
Medicare Billing
$17,973
Payment Breakdown by Category
Research$9,375 (60.1%)
Consulting$4,835 (31.0%)
Food & Beverage$1,094 (7.0%)
Other$300.00 (1.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $9,375 | 10 | 60.1% |
| Consulting Fee | $4,835 | 7 | 31.0% |
| Food and Beverage | $1,094 | 10 | 7.0% |
| Honoraria | $300.00 | 1 | 1.9% |
Payments by Type
Research
$9,375
9 transactions
General
$6,229
18 transactions
Ownership
$0
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Sage Therapeutics, Inc. | $12,575 | 13 | $0 (2021) |
| UCB, Inc. | $1,133 | 3 | $0 (2024) |
| Ceribell, Inc. | $1,085 | 5 | $0 (2023) |
| BARD PERIPHERAL VASCULAR, INC. | $300.00 | 1 | $0 (2019) |
| ARGENX US, INC. | $156.63 | 2 | $0 (2023) |
| SK Life Science, Inc. | $117.60 | 1 | $0 (2023) |
| Eisai Inc. | $89.61 | 1 | $0 (2023) |
| Lilly USA, LLC | $77.94 | 1 | $0 (2023) |
| Biogen, Inc. | $69.03 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $98.25 | 1 | UCB, Inc. ($98.25) |
| 2023 | $1,042 | 7 | Ceribell, Inc. ($600.00) |
| 2021 | $7,966 | 6 | Sage Therapeutics, Inc. ($7,875) |
| 2020 | $5,735 | 10 | Sage Therapeutics, Inc. ($4,700) |
| 2019 | $395.90 | 2 | BARD PERIPHERAL VASCULAR, INC. ($300.00) |
| 2018 | $367.57 | 2 | Ceribell, Inc. ($298.54) |
All Payment Transactions
28 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | UCB, Inc. | — | Food and Beverage | In-kind items and services | $98.25 | General |
| 10/18/2023 | ARGENX US, INC. | VYVGART (Drug) | Food and Beverage | In-kind items and services | $70.81 | General |
| Category: Immunology | ||||||
| 09/09/2023 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $89.61 | General |
| 06/08/2023 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $117.60 | General |
| 05/12/2023 | Lilly USA, LLC | EMGALITY (Drug), REYVOW | Food and Beverage | In-kind items and services | $77.94 | General |
| Category: Neuroscience | ||||||
| 05/01/2023 | Ceribell, Inc. | Ceribell Rapid Response EEG (Device) | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| Category: Neurology | ||||||
| 04/24/2023 | ARGENX US, INC. | VYVGART (Drug) | Food and Beverage | In-kind items and services | $85.82 | General |
| Category: Immunology | ||||||
| 2023 | Ceribell, Inc. | — | — | — | $0.00 | Ownership |
| 12/03/2021 | Ceribell, Inc. | Ceribell Rapid Response EEG (Device) | Food and Beverage | Cash or cash equivalent | $90.77 | General |
| Category: Neurology | ||||||
| 05/21/2021 | Sage Therapeutics, Inc. | ZULRESSO (Drug) | — | Cash or cash equivalent | $1,750.00 | Research |
| Study: A STUDY OF BREXANOLONE FOR ACUTE RESPIRATORY DISTRESS SYNDROME DUE TO COVID-19 • Category: PSYCHIATRYPSYCHOLOGY | ||||||
| 04/30/2021 | Sage Therapeutics, Inc. | ZULRESSO (Drug) | — | Cash or cash equivalent | $1,375.00 | Research |
| Study: A STUDY OF BREXANOLONE FOR ACUTE RESPIRATORY DISTRESS SYNDROME DUE TO COVID-19 • Category: PSYCHIATRYPSYCHOLOGY | ||||||
| 03/30/2021 | Sage Therapeutics, Inc. | ZULRESSO (Drug) | — | Cash or cash equivalent | $1,625.00 | Research |
| Study: A STUDY OF BREXANOLONE FOR ACUTE RESPIRATORY DISTRESS SYNDROME DUE TO COVID-19 • Category: PSYCHIATRYPSYCHOLOGY | ||||||
| 02/26/2021 | Sage Therapeutics, Inc. | ZULRESSO (Drug) | — | Cash or cash equivalent | $1,500.00 | Research |
| Study: A STUDY OF BREXANOLONE FOR ACUTE RESPIRATORY DISTRESS SYNDROME DUE TO COVID-19 • Category: PSYCHIATRYPSYCHOLOGY | ||||||
| 01/22/2021 | Sage Therapeutics, Inc. | ZULRESSO (Drug) | — | Cash or cash equivalent | $1,625.00 | Research |
| Study: A STUDY OF BREXANOLONE FOR ACUTE RESPIRATORY DISTRESS SYNDROME DUE TO COVID-19 • Category: PSYCHIATRYPSYCHOLOGY | ||||||
| 12/01/2020 | UCB, Inc. | Briviact (Drug) | Consulting Fee | Cash or cash equivalent | $690.00 | General |
| Category: Neurology | ||||||
| 12/01/2020 | UCB, Inc. | Briviact (Drug) | Consulting Fee | Cash or cash equivalent | $345.00 | General |
| Category: Neurology | ||||||
| 11/10/2020 | Sage Therapeutics, Inc. | ZULRESSO (Drug) | — | Cash or cash equivalent | $375.00 | Research |
| Study: A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF BREXANOLONE IN THE TREATMENT OF ADOLESCENT FEMALE SUBJECTS WITH POSTPARTUM DEPRESSION • Category: PSYCHIATRYPSYCHOLOGY | ||||||
| 11/10/2020 | Sage Therapeutics, Inc. | ZULRESSO (Drug) | — | Cash or cash equivalent | $375.00 | Research |
| Study: A STUDY OF BREXANOLONE FOR ACUTE RESPIRATORY DISTRESS SYNDROME DUE TO COVID-19 • Category: PSYCHIATRYPSYCHOLOGY | ||||||
| 11/09/2020 | Sage Therapeutics, Inc. | ZULRESSO (Drug) | — | Cash or cash equivalent | $500.00 | Research |
| Study: A STUDY OF BREXANOLONE FOR ACUTE RESPIRATORY DISTRESS SYNDROME DUE TO COVID-19 • Category: PSYCHIATRYPSYCHOLOGY | ||||||
| 11/09/2020 | Sage Therapeutics, Inc. | ZULRESSO (Drug) | — | Cash or cash equivalent | $250.00 | Research |
| Study: A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF BREXANOLONE IN THE TREATMENT OF ADOLESCENT FEMALE SUBJECTS WITH POSTPARTUM DEPRESSION • Category: PSYCHIATRYPSYCHOLOGY | ||||||
| 08/12/2020 | Sage Therapeutics, Inc. | ZULRESSO (Drug) | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| Category: PSYCHIATRYPSYCHOLOGY | ||||||
| 08/11/2020 | Sage Therapeutics, Inc. | ZULRESSO (Drug) | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| Category: PSYCHIATRYPSYCHOLOGY | ||||||
| 02/21/2020 | Sage Therapeutics, Inc. | ZULRESSO (Drug) | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| Category: PSYCHIATRYPSYCHOLOGY | ||||||
| 02/20/2020 | Sage Therapeutics, Inc. | ZULRESSO (Drug) | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| Category: PSYCHIATRYPSYCHOLOGY | ||||||
| 10/16/2019 | Ceribell, Inc. | — | Food and Beverage | Cash or cash equivalent | $95.90 | General |
| Category: Neurology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A STUDY OF BREXANOLONE FOR ACUTE RESPIRATORY DISTRESS SYNDROME DUE TO COVID-19 | Sage Therapeutics, Inc. | $8,750 | 7 |
| A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF BREXANOLONE IN THE TREATMENT OF ADOLESCENT FEMALE SUBJECTS WITH POSTPARTUM DEPRESSION | Sage Therapeutics, Inc. | $625.00 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 49 | 54 | $27,070 | $6,384 |
| 2022 | 1 | 22 | 30 | $20,340 | $5,668 |
| 2021 | 2 | 30 | 32 | $29,328 | $5,922 |
Total Patients
101
Total Services
116
Medicare Billing
$17,973
Procedure Codes
5
All Medicare Procedures & Services
5 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 23 | 28 | $18,984 | $5,172 | 27.2% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Facility | 2023 | 26 | 26 | $8,086 | $1,212 | 15.0% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 22 | 30 | $20,340 | $5,668 | 27.9% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 14 | 16 | $10,848 | $3,065 | 28.3% |
| 95721 | Continuous measurement of brain wave activity (eeg), 37-60 hours, with health care professional analysis, interpretation and report | Facility | 2021 | 16 | 16 | $18,480 | $2,857 | 15.5% |
About Dr. Thomas Bleck, MD
Dr. Thomas Bleck, MD is a Critical Care Medicine healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1548288525.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Bleck, MD has received a total of $15,604 in payments from pharmaceutical and medical device companies, with $98.25 received in 2024. These payments were reported across 28 transactions from 9 companies. The most common payment nature is "" ($9,375).
As a Medicare-enrolled provider, Bleck has provided services to 101 Medicare beneficiaries, totaling 116 services with total Medicare billing of $17,973. Data is available for 3 years (2021–2023), covering 5 distinct procedure/service records.
Ad
Practice Information
- Specialty Critical Care Medicine
- Other Specialties Neurology, Clinical Neurophysiology
- Location Chicago, IL
- Active Since 07/17/2006
- Last Updated 03/07/2023
- Taxonomy Code 207RC0200X
- Entity Type Individual
- NPI Number 1548288525
Products in Payments
- ZULRESSO (Drug) $12,575
- Briviact (Drug) $1,035
- Ceribell Rapid Response EEG (Device) $690.77
- VYVGART (Drug) $156.63
- EMGALITY (Drug) $77.94
- TYSABRI (Biological) $69.03
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Critical Care Medicine Doctors in Chicago
Momen Wahidi, M.d, M.D
Critical Care Medicine — Payments: $903,966
Critical Care Medicine $903,966
Michael Cuttica, Md, MD
Critical Care Medicine — Payments: $398,508
Critical Care Medicine $398,508
Israel Rubinstein
Critical Care Medicine — Payments: $236,380
Critical Care Medicine $236,380
Dr. Eric Gluck, M.d, M.D
Critical Care Medicine — Payments: $161,599
Critical Care Medicine $161,599
Robert Balk, M.d, M.D
Critical Care Medicine — Payments: $57,822
Critical Care Medicine $57,822
Ahmad Abu Homoud
Critical Care Medicine — Payments: $24,062
Critical Care Medicine $24,062